Thus, the first in human study of MANP in essential hypertension is transformational in hypertension therapeutics and establishes that treatment with the designer ANP analog MANP engages the GC-A receptor, activates cGMP, reduces BP, enhances sodium excretion and suppresses aldosterone. The gene discussed is NPPA; the disease is Hypertension.